Valuation dashboard for Prenetics Global Limited (PRE) with P/E N/A, P/B 4.43, EV/EBITDA -5.98 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
Analysis Summary
Prenetics Global Limited reported revenue of $92.4M in the most recent fiscal year, growing at a 5-year CAGR of 7.2%.
Trailing-twelve-month margins: gross margin 62.6%, operating margin -35.2%, net margin -47.4%.
At the current price of $24.19, PRE has negative trailing earnings (P/E not meaningful) and an ROE of -49.17%. Market capitalisation stands at $411M.
Balance sheet quality for PRE: current ratio of 3.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.43 |
| EV / EBITDA | -5.98 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-985.98 |
| vs Current Price | -4176.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PRE | Prenetics Global Limited | $411M | 4.43 | -49.2% | |
| TMO | Thermo Fisher Scientific Inc. | $244.6B | 36.71 | 4.81 | 13.4% |
| 0R0H.L | Thermo Fisher Scientific Inc. | $244.6B | 35.47 | 4.45 | 12.6% |
| 0R2B.L | Danaher Corporation | $150.1B | |||
| DHR | Danaher Corporation | $149.3B | 39.34 | 2.98 | 7.7% |
| NTRA | Natera, Inc. | $52.5B | 30.51 | -11.7% | |
| 0HAV.L | Agilent Technologies, Inc. | $49.8B | 30.76 | 6.00 | 20.5% |
| 0JDM.L | IQVIA Holdings Inc. | $45.7B |
Price
| Price | $24.19 |
| Market Cap | $411M |
| Exchange | NASDAQ |
| Country | HK |
Profitability
| Return on Equity | -49.17% |
| Return on Invested Capital | -42.66% |
| Return on Assets | -44.00% |
| Gross Margin | 62.61% |
| Operating Margin | -35.20% |
| Net Margin | -47.43% |
Related companies: ARMP · ATLN · CDXS · IMDX · MXCT · OSUR · PROF
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of PRE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks